Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent.~* Male or female subjects, 18 years of age.~* Confirmed diagnosis of Crohn's Disease.~* Subject must have a 3 month documented history of perianal Crohn's Disease (PCD) and with clinical evidence of active PCD.~* Subject must have a Crohn's Disease Activity Index (CDAI) total score of ≤ 350 at Visit 2.~* Subjects must have a qualifying perianal pain score at Visits 1 and 2.~Exclusion Criteria:~* Women of childbearing potential who are not using adequate contraception.~* Women who are pregnant or breastfeeding.~* Subjects on unstable regimens of Crohn's therapy (e.g. tumor necrosis factor (TNF) inhibitors, immunosuppressants, steroids).~* Subjects taking strong analgesics that could interfere with pain measurements. Subjects with a perianal abscess requiring incision and drainage.~* Subjects with anal stenosis.~* Subjects with fistulae outside the immediate perianal area.~* Subjects who have had abdominal surgery for Crohn's disease within the past 12 weeks.~* Subjects who have had significant anorectal surgery for Crohns disease within the past 8 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLI-1300 (low dose) (Type: EXPERIMENTAL): Investigational Product (10%) Ointment
- BLI-1300 (high dose) (Type: EXPERIMENTAL): Investigational Product (20%) Ointment
- placebo (Type: PLACEBO_COMPARATOR): Placebo Ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).